MarketVIEW STD & Sexual Health Vaccines  ·  April 2025 edition

Chlamydia trachomatis
Vaccines Forecast

Chlamydia trachomatis caused an estimated 128.5 million new infections worldwide in 2020, yet decades of vaccine research produced only early-stage candidates. That changed in March 2025, when Sanofi's mRNA candidate received FDA Fast Track designation and entered human trials, alongside Statens Serum Institut's CTH522 advancing toward dual urogenital and ocular Phase 2 testing. This is the independent commercial assessment of what a workable vaccine could be worth, drawing on VacZine Analytics' long-standing, independent authority in STD vaccine markets.

Sanofi mRNA Candidate FDA Fast Tracked (2025) 128.5M New Infections in 2020 18 High-Income Nations + BRICM + GAVI Leading Cause of Infectious Blindness
Product catalogue
VAMV003
April 2025 edition

Format
PDF (>225 slides) + Excel
Coverage
18 HIC + BRICM + GAVI (40)
Vaccines assessed
CTH522, Sanofi mRNA, Ziphius
Profiles
Urogenital + ocular (trachoma)
Approach
Scenario-based
Base edition
April 2025
Availability
Syndicated / bespoke
128.5M
New Chlamydia trachomatis
infections worldwide in 2020
4.0%
Global prevalence in women
aged 15 to 49 (WHO)
50%
WHO 2030 target reduction
in new chlamydia cases
2025
Year Sanofi's mRNA candidate
received FDA Fast Track status
Disease background

Why Chlamydia has remained a vaccine priority for decades

Chlamydia trachomatis is one of the most common infections in humanity, and one whose consequences fall disproportionately on reproductive and ocular health. Understanding both the scale of that burden and why the field's most advanced candidates are only now reaching human trials is central to understanding what a workable vaccine could be worth.

WHO 2020/2021 data & 2025/2026 pipeline

Pathogen overview - Chlamydia trachomatis

Chlamydia trachomatis is a Gram-negative bacterium responsible for one of the most common sexually transmitted infections (STIs) worldwide, causing an estimated 128.5 million new infections in 2020 among adults aged 15 to 49. WHO estimates global prevalence in this age group at 4.0% in women and 2.5% in men. A separate 2021 modelling analysis estimated global incidence at 235.7 million cases and prevalence at 152.2 million, underscoring how widely burden estimates vary depending on methodology, and why WHO launched its first global database on STI prevalence in 2026 to help standardise the evidence base across 766 studies and more than 2,450 data points.

Although infection is mostly asymptomatic, in women untreated ascending infections can result in severe sexual and reproductive health outcomes, including pelvic inflammatory disease, ectopic pregnancy and infertility. Chlamydia infection also elevates the risk of HIV acquisition and transmission, and can cause neonatal conjunctivitis, itself a cause of blindness in newborns. In the developing world, ocular C. trachomatis infection causes trachoma, the leading cause of infectious blindness worldwide. Although chlamydia infections are generally treatable with antibiotics, the bacterium has a high rate of reinfection, driven by silent, asymptomatic carriage in younger populations, and WHO's Global Health Sector Strategy on HIV, Viral Hepatitis and STIs 2022 to 2030 sets a target of a 50% reduction in new chlamydia cases by 2030.

A prophylactic, chlamydia-specific vaccine that reduces infection or shortens disease course could meaningfully reduce these adverse outcomes and lower reliance on antibiotic treatment. Such a vaccine could be targeted routinely to adolescents and young adults, or to high-risk groups such as gay, bisexual and other men who have sex with men (GBMSM), who account for a disproportionate share of diagnoses, and could offer dual utility against both genital and ocular disease in developing-world settings.

The field has moved from decades of preclinical effort to a regulatory-backed human-trial programme within the past two years. Statens Serum Institut's CTH522, adjuvanted with CAF01 or CAF09b liposomes, completed a Phase 1 trial (CHLM-02, 65 participants enrolled 2020 to 2022, published in The Lancet Infectious Diseases in 2024) showing a favourable safety profile and robust neutralising antibody responses against both trachoma (serovar B) and urogenital (serovar D) strains, and it is now advancing toward Phase 2 testing of both indications. In March 2025, Sanofi's multi-antigen mRNA candidate received FDA Fast Track designation and entered a Phase 1/2 trial (adults aged 18 to 29, three intramuscular doses, 12 month follow-up), designed to protect against both primary infection and reinfection. Ziphius's self-amplifying RNA (saRNA) candidate remains preclinical, alongside earlier-stage academic programmes from Abera and the University of North Carolina School of Medicine.

2026 128.5M new infections in 2020  |  leading cause of infectious blindness worldwide  |  Sanofi mRNA candidate FDA Fast Tracked, in Phase 1/2  |  CTH522 advancing toward Phase 2
Product & competitor landscape

From decades of preclinical effort to a regulatory-backed frontrunner

Chlamydia vaccine development has historically lagged far behind other STI programmes. That gap has narrowed sharply over the past two years, with two candidates now in active human testing and a regulatory designation that signals renewed institutional confidence in the field.

  • Statens Serum InstitutPhase 1 complete
    CTH522 Urogenital + ocular
    A subunit vaccine adjuvanted with CAF01 or CAF09b liposomes (or aluminium hydroxide). The CHLM-02 Phase 1 trial (65 participants, 2020 to 2022) showed a favourable safety profile and robust neutralising antibody responses against both trachoma (serovar B) and urogenital (serovar D) strains, published in The Lancet Infectious Diseases in 2024. Now advancing toward Phase 2 testing of both indications.
  • SanofiPhase 1/2, FDA Fast Track
    Multi-antigen mRNA candidate
    Received FDA Fast Track designation in March 2025. A Phase 1/2 trial in adults aged 18 to 29 is evaluating three intramuscular doses against placebo, with 12 months of follow-up, designed to protect against primary genital tract infection and reinfection. The trial's registered enrollment target was revised down from 1,560 to 80 participants on ClinicalTrials.gov (NCT06891417) in early November 2026; the trial remains listed as recruiting and the designation is unchanged.
  • ZiphiusPreclinical
    Self-amplifying RNA (saRNA) candidate
    An earlier-stage saRNA approach, part of a broader wave of nucleic-acid platforms being applied to chlamydia after decades of subunit-dominated research.
  • Academic programmesPreclinical
    Abera and UNC School of Medicine, among others
    Earlier-stage academic and biotech programmes continue to broaden the field's antigen and platform diversity beyond the two candidates now in clinical testing.
Field inflection point
2025

Sanofi's FDA Fast Track designation marks a first for the chlamydia vaccine field: after decades in which CTH522 stood largely alone in early clinical testing, a major manufacturer now has a regulatory-backed programme moving through human trials. The underlying opportunity is exceptionally broad, spanning routine adolescent immunization, high-risk group targeting, and developing-world trachoma control. The VacZine Analytics model quantifies the commercial opportunity under multiple pipeline-progression scenarios across both vaccine profiles.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW Chlamydia trachomatis analysis spans disease burden, target-population rationale, the post-2025 competitor landscape and scenario-based revenue forecasting across 18 high-income nations, BRICM and GAVI-eligible markets.

Patient forecast across 40+ countries

Bottom-up modelling across 18 high-income nations, plus BRICM and GAVI-eligible markets (40 countries), public and private.

Competitor & pipeline review

CTH522's Phase 1 data and Phase 2 plans, Sanofi's FDA Fast Tracked mRNA candidate, Ziphius's saRNA approach and academic programmes.

Dual-profile vaccinology assessment

Commercial and clinical feasibility of urogenital and ocular (trachoma) vaccine profiles, including target population rationale.

Scenario-based revenue forecasts

Base, upside and conservative scenarios across public and private markets, adolescent/young adult and high-risk target groups.

Disease burden & epidemiology

Updated global STI burden estimates drawing on WHO's 2026 global prevalence database, and reproductive health/trachoma sequelae.

Target population & access strategy

Uptake, pricing and clinical development feasibility across adolescent/young adult, GBMSM and developing-world trachoma programmes.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the target-population and scenario framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.

Target populationGeographyMarket typeVaccine profileRevenue scenario
Adolescents / young adults (routine)18 high-income nationsPublic + privateUrogenitalModelled
GBMSM high-risk cohortHigh-income nationsPrivateUrogenitalModelled
Developing-world trachoma programmesBRICM + GAVI (40)Public programmeOcularModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseGlobalAllAll profiles$███m
Full model in the licensed workbook
18 HIC + BRICM + GAVI · dual profile · target group · pricing detail
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for decision-makers who need the full picture on the Chlamydia trachomatis vaccine opportunity.

  • Executive presentation (>225 slides, PDF) - disease background, epidemiology, competitor pipeline, target population rationale and full commercial assessment with supporting narrative and references
  • Interactive MS-Excel forecast model (150 worksheets) - scenario-based volume and revenue outputs across 18 high-income nations, BRICM and GAVI-eligible markets
  • Scenario-based commercial forecasts - base, upside and conservative cases reflecting the post-2025 pipeline inflection
  • Competitor intelligence - CTH522 (Statens Serum Institut), Sanofi's FDA Fast Tracked mRNA candidate, Ziphius saRNA, and academic programmes
  • Updated epidemiology module - global STI burden drawing on WHO's 2026 global prevalence database, reproductive health sequelae, and trachoma blindness data
  • Target population & access assessment - uptake, pricing and clinical development feasibility across urogenital and ocular vaccine profiles
Target audience

Built for organisations weighing the Chlamydia opportunity

Most valuable to teams evaluating the Chlamydia trachomatis vaccine market against their own pipeline, BD ambitions or investment thesis, particularly in light of Sanofi's 2025 Fast Track designation and CTH522's advance toward Phase 2.

Vaccine developers

Positioning, commercial feasibility and target-population prioritisation for chlamydia candidates at any stage.

Corporate strategy & BD

Validate the market size and structure now that a major manufacturer has entered clinical development.

Investors & analysts

Independent assessment of market size and pipeline risk for due diligence on chlamydia and adjacent STD vaccine assets.

Public health & global health programmes

Demand modelling for sexual health, adolescent immunization and developing-world trachoma control programmes.

Researchers & academia

Comprehensive epidemiology and vaccine landscape for grant and translational planning, including CTH522 and mRNA platform data.

Market access & policy

Pricing benchmarks and access-pathway assumptions across public and private sexual health and global health channels.

About this analysis · VAMV003

VacZine Analytics has tracked STD vaccine markets since our earliest editions, positioning us to reassess the Chlamydia trachomatis opportunity the moment the pipeline changed. This analysis combines a rigorous epidemiological and clinical review with an independently constructed commercial model spanning 18 high-income nations, BRICM and GAVI-eligible markets that most forecasts model only in aggregate. Few groups have followed this market as closely or for as long, and that recognised, independent expertise underpins everything in the analysis, which has been well received by clients across the field.

This April 2025 edition incorporates Sanofi's March 2025 FDA Fast Track designation and Phase 1/2 trial start, alongside CTH522's published Phase 1 data and Phase 2 plans. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV003 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Chlamydia analysis, a briefing call is included on request.